{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:59:07Z","timestamp":1762549147234,"version":"build-2065373602"},"reference-count":108,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006506","name":"Ministry of Health","doi-asserted-by":"publisher","award":["406775\/2022-2"],"award-info":[{"award-number":["406775\/2022-2"]}],"id":[{"id":"10.13039\/501100006506","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019198","name":"Instituto Nacional de Ci\u00eancia e Tecnologia em Teran\u00f3stica e Nanobiotecnologia","doi-asserted-by":"publisher","award":["CNPq-465669\/2014-0"],"award-info":[{"award-number":["CNPq-465669\/2014-0"]}],"id":[{"id":"10.13039\/100019198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clbc.2025.04.019","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T02:59:31Z","timestamp":1745981971000},"page":"e920-e934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Navigating Endocrine Sensitivity Assessment in Nonmetastatic Breast Cancer Through Early On-Treatment Ki67 Understanding"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7934-1451","authenticated-orcid":false,"given":"Carlos Eduardo","family":"Paiva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitor Souza","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alinne Tatiane Faria","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yara Cristina de Paiva","family":"Maia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca Sakamoto Ribeiro","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1s","family":"Reinert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"LeVasseur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clbc.2025.04.019_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-022-00363-1","article-title":"Breast cancer heterogeneity and its implication in personalized precision therapy","volume":"12","author":"Guo","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.04.019_bib0002","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s12885-018-4388-4","article-title":"Genes and functions from breast cancer signatures","volume":"18","author":"Huang","year":"2018","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.clbc.2025.04.019_bib0003","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2478\/raon-2019-0038","article-title":"Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer","volume":"53","author":"Ovcaricek","year":"2019","journal-title":"Radiol Oncol"},{"issue":"6871","key":"10.1016\/j.clbc.2025.04.019_bib0004","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"van \u2019t Veer","year":"2002","journal-title":"Nature"},{"issue":"27","key":"10.1016\/j.clbc.2025.04.019_bib0005","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.clbc.2025.04.019_bib0006","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1158\/1078-0432.CCR-11-0926","article-title":"A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors","volume":"17","author":"Filipits","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.clbc.2025.04.019_bib0007","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1073\/pnas.0932692100","article-title":"Repeated observation of breast tumor subtypes in independent gene expression data sets","volume":"100","author":"Sorlie","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"10.1016\/j.clbc.2025.04.019_bib0008","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1158\/1078-0432.CCR-23-4020","article-title":"Gene expression assays to tailor adjuvant endocrine therapy for HR+\/HER2- breast cancer","volume":"30","author":"Bottosso","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clbc.2025.04.019_bib0009","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.clbc.2025.04.019_bib0010","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.clbc.2025.04.019_bib0011","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO Guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clbc.2025.04.019_bib0012","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","article-title":"Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis","volume":"2","author":"Spring","year":"2016","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2025.04.019_bib0013","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10549-019-05397-4","article-title":"Utilization, duration, and outcomes of neoadjuvant endocrine therapy in the United States","volume":"178","author":"Pariser","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.clbc.2025.04.019_bib0014","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10549-018-4964-y","article-title":"Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study","volume":"173","author":"Iwata","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2025.04.019_bib0015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.breast.2021.04.010","article-title":"Clinical utility of the 21-gene assay in predicting response to neoadjuvant endocrine therapy in breast cancer: a systematic review and meta-analysis","volume":"58","author":"Davey","year":"2021","journal-title":"Breast"},{"issue":"5","key":"10.1016\/j.clbc.2025.04.019_bib0016","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/modpathol.2013.36","article-title":"Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis","volume":"26","author":"Klein","year":"2013","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.clbc.2025.04.019_bib0017","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1038\/s41379-020-0521-4","article-title":"The healthcare value of the Magee Decision AlgorithmTM: use of Magee EquationsTM and mitosis score to safely forgo molecular testing in breast cancer","volume":"33","author":"Bhargava","year":"2020","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.clbc.2025.04.019_bib0018","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/modpathol.2017.41","article-title":"Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative\/equivocal breast tumors","volume":"30","author":"Farrugia","year":"2017","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.clbc.2025.04.019_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16020339","article-title":"The magee 3 equation predicts favorable pathologic response to neoadjuvant endocrine therapy in breast cancer patients","volume":"16","author":"Paiva","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.clbc.2025.04.019_bib0020","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","article-title":"Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial","volume":"21","author":"Smith","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2025.04.019_bib0021","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1470-2045(09)70262-1","article-title":"Ki67 in breast cancer: prognostic and predictive potential","volume":"11","author":"Yerushalmi","year":"2010","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clbc.2025.04.019_bib0022","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/jnci\/djaa201","article-title":"Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group","volume":"113","author":"Nielsen","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2025.04.019_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.687244","article-title":"The role of Ki67 in evaluating neoadjuvant endocrine therapy of hormone receptor-positive breast cancer","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6319","key":"10.1016\/j.clbc.2025.04.019_bib0024","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/bmj.284.6319.869-a","article-title":"Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study","volume":"284","author":"Preece","year":"1982","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"5","key":"10.1016\/j.clbc.2025.04.019_bib0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11864-018-0538-9","article-title":"Current status of neoadjuvant endocrine therapy in early stage breast cancer","volume":"19","author":"Reinert","year":"2018","journal-title":"Curr Treat Options Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2025.04.019_bib0026","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1055\/s-0036-1597579","article-title":"Multidisciplinary Approach to neoadjuvant endocrine therapy in breast cancer: a comprehensive review","volume":"38","author":"Reinert","year":"2016","journal-title":"Rev Bras Ginecol Obstet"},{"issue":"17","key":"10.1016\/j.clbc.2025.04.019_bib0027","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.2010.31.6950","volume":"29","author":"Ellis","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2025.04.019_bib0028","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1245\/s10434-016-5585-5","article-title":"Trends in neoadjuvant endocrine therapy use and impact on rates of breast conservation in hormone receptor-positive breast cancer: a national cancer data base study","volume":"24","author":"Chiba","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"9938","key":"10.1016\/j.clbc.2025.04.019_bib0029","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet (London, England)"},{"issue":"15","key":"10.1016\/j.clbc.2025.04.019_bib0030","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.04.019_bib0031","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/14737140.2023.2162043","article-title":"Neoadjuvant endocrine therapy in postmenopausal women with HR+\/HER2- breast cancer","volume":"23","author":"Mart\u00ednez-P\u00e9rez","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"10.1016\/j.clbc.2025.04.019_bib0032","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ijc.2910310104","article-title":"Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation","volume":"31","author":"Gerdes","year":"1983","journal-title":"Int J cancer"},{"issue":"19","key":"10.1016\/j.clbc.2025.04.019_bib0033","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/jnci\/djn309","article-title":"Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics","volume":"100","author":"Ellis","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"10.1016\/j.clbc.2025.04.019_bib0034","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/jnci\/djn309","article-title":"Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics","volume":"100","author":"Ellis","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.clbc.2025.04.019_bib0035","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jnci\/djk020","article-title":"Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer","volume":"99","author":"Dowsett","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.clbc.2025.04.019_bib0036","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jamcollsurg.2009.01.035","article-title":"Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial","volume":"208","author":"Olson","year":"2009","journal-title":"J Am Coll Surg"},{"issue":"10","key":"10.1016\/j.clbc.2025.04.019_bib0037","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2016.69.4406","article-title":"Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: Results from the American college of surgeons oncology group Z1031 trial (alliance)","volume":"35","author":"Ellis","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clbc.2025.04.019_bib0038","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2016.69.4406","article-title":"Ki67 Proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 Trial (Alliance)","volume":"35","author":"Ellis","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2025.04.019_bib0039","article-title":"The ALTERNATE trial: Assessing a biomarker driven strategy for the treatment of post-menopausal women with Er+\/Her2- invasive breast cancer","volume":"4","author":"Suman","year":"2015","journal-title":"Chinese Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clbc.2025.04.019_bib0040","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2020.38.15_suppl.504","article-title":"ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106","volume":"38","author":"Ma","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2025.04.019_bib0041","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10549-017-4329-y","article-title":"Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer","volume":"165","author":"Goncalves","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.clbc.2025.04.019_bib0042","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s10549-020-06076-5","article-title":"Real-world data on neoadjuvant endocrine therapy in ER-positive\/HER2-negative breast cancer","volume":"186","author":"da Silva","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.clbc.2025.04.019_bib0043","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/jcp-2022-208731","article-title":"Expression, assessment and significance of Ki67 expression in breast cancer: an update","volume":"76","author":"Lashen","year":"2023","journal-title":"J Clin Pathol"},{"issue":"25","key":"10.1016\/j.clbc.2025.04.019_bib0044","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1200\/JCO.2013.54.1870","article-title":"Luminal B breast cancer: molecular characterization, clinical management, and future perspectives","volume":"32","author":"Ades","year":"2014","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clbc.2025.04.019_bib0045","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133390","article-title":"Role of glucose metabolic reprogramming in breast cancer progression and drug resistance","volume":"15","author":"Lei","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.clbc.2025.04.019_bib0046","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1001\/jamaoncol.2023.6038","article-title":"Endocrine-sensitive disease rate in postmenopausal patients with estrogen receptor-rich\/ERBB2-negative breast cancer receiving neoadjuvant anastrozole, fulvestrant, or their combination: a phase 3 randomized clinical trial","volume":"10","author":"Ma","year":"2024","journal-title":"JAMA Oncol"},{"issue":"15","key":"10.1016\/j.clbc.2025.04.019_bib0047","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-16-3206","article-title":"NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.clbc.2025.04.019_bib0048","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1158\/1078-0432.CCR-22-0068","article-title":"Evaluation of sensitivity to endocrine therapy index (SET2,3) for response to neoadjuvant endocrine therapy and longer-term breast cancer patient outcomes (Alliance Z1031)","volume":"28","author":"Suman","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clbc.2025.04.019_bib0049","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13058-020-01314-6","article-title":"Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines","volume":"22","author":"Madigan","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2025.04.019_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113358","article-title":"Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive\/HER2-negative early breast cancer: a systematic review and meta-analysis","volume":"194","author":"Martins-Branco","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2025.04.019_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103900","article-title":"Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives","volume":"181","author":"Sirico","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.clbc.2025.04.019_bib0052","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217279","article-title":"Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy","volume":"14","author":"Kurozumi","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.clbc.2025.04.019_bib0053","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s13193-022-01665-w","article-title":"Fall in Ki67 index after short-term preoperative letrozole: a gateway to assess the response in hormone-positive early breast cancers","volume":"14","author":"Louis","year":"2023","journal-title":"Indian J Surg Oncol"},{"issue":"4","key":"10.1016\/j.clbc.2025.04.019_bib0054","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.3390\/curroncol29040179","article-title":"The clinical impact of neoadjuvant endocrine treatment on luminal-like breast cancers and its prognostic significance: results from a single-institution prospective cohort study","volume":"29","author":"Mart\u00ed","year":"2022","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.04.019_bib0055","article-title":"Biomarker alteration after neoadjuvant endocrine therapy or chemotherapy in estrogen receptor-positive breast cancer","volume":"13","author":"Long","year":"2022","journal-title":"Life (Basel, Switzerland)"},{"issue":"2","key":"10.1016\/j.clbc.2025.04.019_bib0056","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10549-018-4933-5","article-title":"Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling","volume":"172","author":"Goto-Yamaguchi","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.clbc.2025.04.019_bib0057","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/B:BREA.0000003968.45511.3f","article-title":"Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer","volume":"82","author":"Assersohn","year":"2003","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.clbc.2025.04.019_bib0058","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1200\/JCO.1999.17.10.3058","article-title":"Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer","volume":"17","author":"Chang","year":"1999","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2025.04.019_bib0059","first-page":"616","article-title":"Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients","volume":"6","author":"Chang","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clbc.2025.04.019_bib0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1023\/A:1005973529921","article-title":"Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response","volume":"48","author":"Makris","year":"1998","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.clbc.2025.04.019_bib0061","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1023\/A:1006179511178","article-title":"Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study","volume":"53","author":"Makris","year":"1999","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.clbc.2025.04.019_bib0062","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","article-title":"Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021","volume":"32","author":"Burstein","year":"2021","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.04.019_bib0063","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13058-017-0913-7","article-title":"Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4\/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib","volume":"19","author":"Bagegni","year":"2017","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.clbc.2025.04.019_bib0064","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10549-023-06893-4","article-title":"Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study","volume":"199","author":"Dave","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"10.1016\/j.clbc.2025.04.019_bib0065","first-page":"614","article-title":"EZH2 protein expression in estrogen receptor positive invasive breast cancer treated with neoadjuvant endocrine therapy: an exploratory study of association with tumor response","volume":"30","author":"Gan","year":"2022","journal-title":"Appl Immunohistochem Mol Morphol AIMM"},{"key":"10.1016\/j.clbc.2025.04.019_bib0066","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/1745-6215-14-261","volume":"14","author":"Hofmann","year":"2013","journal-title":"Trials"},{"issue":"7","key":"10.1016\/j.clbc.2025.04.019_bib0067","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/cam4.1600","article-title":"Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study","volume":"7","author":"Sato","year":"2018","journal-title":"Cancer Med"},{"issue":"12","key":"10.1016\/j.clbc.2025.04.019_bib0068","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.1002\/cam4.2423","article-title":"Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks\u2019 exemestane exposure in patients with estrogen receptor-positive breast cancer: a multicenter, open-label, phase II study","volume":"8","author":"Sato","year":"2019","journal-title":"Cancer Med"},{"issue":"10","key":"10.1016\/j.clbc.2025.04.019_bib0069","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1158\/1078-0432.CCR-18-3160","article-title":"A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NEO-ORB)","volume":"25","author":"Mayer","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clbc.2025.04.019_bib0070","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13058-015-0532-0","article-title":"Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer","volume":"17","author":"L\u00f3pez-Knowles","year":"2015","journal-title":"Breast Cancer Res"},{"issue":"3","key":"10.1016\/j.clbc.2025.04.019_bib0071","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1054\/brst.2002.0408","article-title":"MIB-1 assessments in breast cancers","volume":"11","author":"Iqbal","year":"2002","journal-title":"Breast"},{"issue":"7","key":"10.1016\/j.clbc.2025.04.019_bib0072","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/sj.bjc.6603001","article-title":"Proliferation, steroid receptors and clinical\/pathological response in breast cancer treated with letrozole","volume":"94","author":"Miller","year":"2006","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2025.04.019_bib0073","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/A:1005933815809","article-title":"Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy","volume":"48","author":"Ellis","year":"1998","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.clbc.2025.04.019_bib0074","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1530\/ERC-11-0180","article-title":"Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer","volume":"18","author":"Bedard","year":"2011","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.clbc.2025.04.019_bib0075","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1078-0432.CCR-19-1425","article-title":"Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR+\/HER2- breast cancer","volume":"26","author":"Hurvitz","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clbc.2025.04.019_bib0076","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40644-020-0287-4","article-title":"Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response","volume":"20","author":"Boughdad","year":"2020","journal-title":"Cancer Imaging"},{"issue":"3s","key":"10.1016\/j.clbc.2025.04.019_bib0077","doi-asserted-by":"crossref","first-page":"1024s","DOI":"10.1158\/1078-0432.CCR-05-2127","article-title":"Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer","volume":"12","author":"Dowsett","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.clbc.2025.04.019_bib0078","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.steroids.2011.02.025","article-title":"Association between breast cancer subtypes and response to neoadjuvant anastrozole","volume":"76","author":"Dunbier","year":"2011","journal-title":"Steroids"},{"issue":"10","key":"10.1016\/j.clbc.2025.04.019_bib0079","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-12-1000","article-title":"Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance","volume":"19","author":"Dunbier","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clbc.2025.04.019_bib0080","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10549-022-06525-3","article-title":"Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients","volume":"192","author":"Franzoi","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.clbc.2025.04.019_bib0081","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-021-00377-8","article-title":"Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer","volume":"8","author":"Gianni","year":"2022","journal-title":"NPJ breast cancer"},{"issue":"3","key":"10.1016\/j.clbc.2025.04.019_bib0082","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1200\/JCO.18.01624","article-title":"Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial","volume":"37","author":"Johnston","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2025.04.019_bib0083","article-title":"Use of ultrasound and Ki-67 proliferation index to predict breast cancer tumor response to neoadjuvant endocrine therapy","volume":"11","author":"Liebscher","year":"2023","journal-title":"Healthc (Basel, Switzerland)"},{"issue":"7","key":"10.1016\/j.clbc.2025.04.019_bib0084","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1158\/1078-0432.CCR-10-2567","article-title":"A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance","volume":"17","author":"Miller","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.clbc.2025.04.019_bib0085","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1200\/JCO.2008.18.8391","article-title":"Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer","volume":"27","author":"Baselga","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2025.04.019_bib0086","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10549-021-06214-7","article-title":"ANETT: PhAse II trial of NEoadjuvant TAK-228 plus tamoxifen in patients with hormone receptor-positive breast cancer","volume":"188","author":"Koca","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.clbc.2025.04.019_bib0087","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10549-009-0523-x","article-title":"A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer","volume":"119","author":"Freedman","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2025.04.019_bib0088","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920973130","article-title":"The run-in phase of the prospective WSG-ADAPT HR+\/HER2\u2013 trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer","volume":"12","author":"Nitz","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.04.019_bib0089","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13058-023-01626-3","article-title":"Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER\u2009+\u2009breast cancer: further results from the POETIC trial (CRUK\/07\/015)","volume":"25","author":"Bliss","year":"2023","journal-title":"Breast Cancer Res"},{"issue":"10","key":"10.1016\/j.clbc.2025.04.019_bib0090","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/s41379-022-01104-9","article-title":"Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study","volume":"35","author":"Acs","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clbc.2025.04.019_bib0091","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/1471-2407-11-341","article-title":"Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies","volume":"11","author":"Romero","year":"2011","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.clbc.2025.04.019_bib0092","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.annonc.2023.08.017","article-title":"Understanding breast cancer complexity to improve patient outcomes: the St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023","volume":"34","author":"Curigliano","year":"2023","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"22","key":"10.1016\/j.clbc.2025.04.019_bib0093","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1200\/JCO.2005.04.005","article-title":"Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.04.019_bib0094","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-020-0168-9","article-title":"Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic","volume":"6","author":"Dowsett","year":"2020","journal-title":"NPJ breast cancer"},{"issue":"23","key":"10.1016\/j.clbc.2025.04.019_bib0095","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1200\/JCO.21.02759","article-title":"Endocrine therapy response and 21-gene expression assay for therapy guidance in HR+\/HER2- early breast cancer","volume":"40","author":"Nitz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clbc.2025.04.019_bib0096","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1200\/JCO.2005.07.559","article-title":"Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer\u2013a study from the IMPACT trialists","volume":"23","author":"Dowsett","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clbc.2025.04.019_bib0097","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10549-007-9701-x","article-title":"Letrozole in the neoadjuvant setting: the P024 trial","volume":"105","author":"Ellis","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"7403","key":"10.1016\/j.clbc.2025.04.019_bib0098","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature11143","article-title":"Whole-genome analysis informs breast cancer response to aromatase inhibition","volume":"486","author":"Ellis","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.clbc.2025.04.019_bib0099","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1038\/s41467-023-39613-z","article-title":"Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers","volume":"14","author":"Schuster","year":"2023","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.clbc.2025.04.019_bib0100","article-title":"Use of ultrasound and Ki-67 proliferation index to predict breast cancer tumor response to neoadjuvant endocrine therapy","volume":"11","author":"Liebscher","year":"2023","journal-title":"Healthc (Basel, Switzerland)"},{"issue":"9","key":"10.1016\/j.clbc.2025.04.019_bib0101","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S1470-2045(19)30334-1","article-title":"Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"20","author":"Saura","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2025.04.019_bib0102","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1093\/annonc\/mdy448","article-title":"Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer","volume":"29","author":"Cottu","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.04.019_bib0103","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1470-2045(19)30786-7","article-title":"Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial","volume":"21","author":"Prat","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2025.04.019_bib0104","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10238-022-00814-3","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors in combination with neoadjuvant endocrine therapy in estrogen receptor-positive early breast cancer: a systematic review and meta-analysis","volume":"23","author":"Guan","year":"2023","journal-title":"Clin Exp Med"},{"issue":"5","key":"10.1016\/j.clbc.2025.04.019_bib0105","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/his.13007","article-title":"Intratumoral heterogeneity of Ki67 expression in early breast cancers exceeds variability between individual tumours","volume":"69","author":"Focke","year":"2016","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.clbc.2025.04.019_bib0106","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00428-017-2142-y","article-title":"Quality assurance trials for Ki67 assessment in pathology","volume":"471","author":"Raap","year":"2017","journal-title":"Virchows Arch"},{"key":"10.1016\/j.clbc.2025.04.019_bib0107","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1221773","article-title":"Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis","volume":"13","author":"Najim","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clbc.2025.04.019_bib0108","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241272463","article-title":"A research protocol for a phase II single-arm clinical trial assessing the feasibility and efficacy of neoadjuvant anastrozole in patients with luminal breast cancer and low proliferative index: the ANNE trial","volume":"31","author":"Paiva","year":"2024","journal-title":"Cancer Control"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925001119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925001119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:57:07Z","timestamp":1762549027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820925001119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":108,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1526820925001119"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2025.04.019","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating Endocrine Sensitivity Assessment in Nonmetastatic Breast Cancer Through Early On-Treatment Ki67 Understanding","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2025.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}